Hemics  started as a LabVenture within Philips Research. After realization of a clinical prototype and a successful clinical trial, the venture raised sufficient money for a spin-out of Philips on September 1st 2011.

Hemics is a contraction of Hemodynamics, which is the base concept used for our optical inflammation technology.